[Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus]

Related Experiment Video

Updated: Jul 2, 2026

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
11:50

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle

Published on: June 8, 2022

Agnieszka Szypowska1, Agata Skórka, Ewa Pańkowska

  • 1Department of Diabeology, Newborn Pathology and Birth Defects, Medical University of Warsaw, Poland. agnieszka.sypowska@gmail.com

Pediatric Endocrinology, Diabetes, and Metabolism
|August 30, 2008
PubMed

Lipoatrophy as a cutaneous complication of insulin therapy has been practically forgotten since the introduction of recombinant human insulin. Here we present two cases of marked lipoatrophy associated with rapid-acting insulin analogues (aspart and lispro) administered with continuous subcutaneous insulin infusion or multiple daily injections in a toddler and a young woman with type 1 diabetes mellitus. The exact mechanisms related to the development of localized lipoatrophy in the insulin injection area are unknown. In cases of lipoatrophy the beneficial therapeutic approach is to change the insulin molecule. With switching from one insulin analogue to another administered in insulin pump and changing the sites of insulin injections no progression of the lipoatrophic lesions was observed. Unfortunately, only decrease but no total regression of the formed lesions was achieved and future studies are needed to establish the method of treatment of localized lipoatrophy in children treated with continuous subcutaneous insulin infusion.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...